Bangkok : HIV vaccine is proven effective against the virus that causes AIDS was eventually found in the test involving more than 16,000 volunteers in Thailand.
U.S. military to provide funds in conjunction with the National Institute of Allergy anf Infections Disease. Parties involved volunteers who come from Chonburi and Rayong provinces mentioned has the most HIV rates in Thailand.
Although the level of benefits achieved is still relatively less, this is the first evidence that we have a preventive vaccine is safe and effective, said Colonel Jerome Kim.
Vaccines are still having the benefits of this small scale has a large impact. every day, 7,500 people worldwide infected with HIV, 2 million people died of AIDS in 2007, according to one agency estimates, UNAIDS.
The study was to test the vaccine on two combi with two main approaches, the first directed at the immune system of HIV and the second to strengthen the response generated. The second vaccine is ALVAC, from Sanofi Pasteur, the vaccines division of French drug producer Sanofi-Aventis and AIDSVAX, which was originally developed by VaxGen Inc. and now held by Global Solutions for Infectious diseases, as nonfrofit institution founded by the former employees of VaxGen.
We conducted a separate test, none of the vaccine could prevent HIV infection in early trials and dozens of specialist teams claimed the test was useless in 2003, when initial testing. then the second combo vaccine, the test back in men and women in Thailand, which proved negative with a range of HIV-infected aged 18 years and 30 years with the risk of infection. Half the participants received two doses of ALVAC and AIDSVAC doses for 6 months. The rest get another vaccine.
Each person is given condoms, counseling and treatment for the infection transferred through sexual intercourse and performed every 6 months of HIV testing. While people with HIV / AIDS receive free treatment and medicines. Participants undergo testing for 3 years after the vaccine was stopped.
Results achieved, new infections appeared in 51 of the 8197 people who received the vaccine and 74 of 8198 who received another injection. Apparently, 31% of vaccine recipients have an increased risk of HIV infection is lower.
The vaccine had no effect on HIV levels contained in the blood that have been infected. Another goal of this study is whether the vaccine can limit the level of damage the immune system and help those who have been infected in order to avoid the full impact of AIDS. The details of the study worth USD 105 million that will be presented in the vaccine conference in Paris in October. This is the third largest trials of the vaccine since 1993, when work on the identification of HIV as the cause of AIDS.
In 2007, Merck & Co.. stop the study of the vaccine in South Africa involving 3000 men and women after a proven failed to prevent HIV infection. The study, which is run jointly by HIV Vaccine Trials Network (HVTN) and South African Aids Vaccine Initiative (SAAVI), finding a vaccine based on HIV type B viruses fail to fight HIV point C. Earlier in 2003, failed in AIDSVAC big test - the test phase of the first AIDS vaccine that will be undertaken at that time.
The good news of the discovery of promising new vaccine after the beginning of September, the two strongest Man antibody against human retroviruses immounodeficiency virus (HIV) causes AIDS syndrome was found and a chance for the change in the form of the vaccine.
As quoted from the journal Nature, the researchers International Aids Vaccine Initiative (IAVI), this discovery is a big leap after a decade of research on a blood sample from a developing country.